Strides Pharma Q4FY26 profit jumps 51% to ₹129 cr

Key takeaway from the quarterly update

Strides Pharma Science Ltd reported a strong year-on-year rise in consolidated profit for the quarter ended March 31, 2026 (Q4FY26), helped by better performance in markets outside the US. The Bengaluru-based generic drugmaker said consolidated net profit rose 51% to ₹129.28 crore, compared with ₹85.62 crore in the year-ago quarter, as per its regulatory filing. Operating revenue for the quarter also increased, with multiple reports putting Q4 revenue from operations at ₹1,323 crore to ₹1,323.47 crore versus ₹1,190.39 crore a year earlier. The company’s update highlighted that demand conditions in the US were relatively flat, with a weak flu season cited as a key factor. Even so, stronger execution and sales growth in non-US geographies lifted overall profitability for the quarter.

What Strides reported for Q4FY26

For Q4FY26, Strides reported operating revenue of about ₹1,323 crore, up 11.2% year-on-year. EBITDA for the quarter was reported at ₹239 crore, translating into an 18.1% EBITDA margin. On the bottom line, consolidated net profit was reported at ₹129.28 crore, a 51% jump over Q4FY25. Another report in the provided material cited Q4 consolidated net profit at ₹126.94 crore (up 54.44% year-on-year), showing a small variation across summaries of the same result set. The company also reported profit before exceptional items and tax of ₹153.01 crore and an exceptional loss of ₹6.41 crore during the quarter.

Non-US markets led the growth

Strides’ Q4 narrative was shaped by stronger traction outside the US. The regulatory filing referenced in the provided content said revenue excluding the US “soared” to ₹645.8 crore for the quarter. Management commentary in the same coverage positioned this as the outcome of a targeted strategy in key non-US markets. This matters because Strides has been managing through uneven demand and category-specific weakness in the US, which can limit growth even when the base business remains stable.

US business stayed muted during FY26

While Q4 performance was supported by non-US growth, the company’s FY26 disclosures pointed to a subdued year for the US segment. Strides’ US business for FY26 was reported at $184 million (₹2,489 crore), described as muted. In contrast, ex-US sales increased 21% year-on-year to ₹2,240 crore ($154 million). The weak flu season was explicitly mentioned as one reason the US business remained largely flat. For investors, these numbers frame where growth contributed most during the year and where momentum was softer.

Full-year FY26: profit lower than FY25 due to one-offs

For FY26, Strides reported total revenue of ₹4,858 crore, up 6.4% year-on-year. Consolidated net profit for FY26 was reported at ₹574.52 crore, with the narrative comparing it to a much higher ₹3,597.51 crore in FY25. The FY25 profit was boosted by profit after tax from discontinued operations of ₹3,188.11 crore, which inflated the year-ago base. The FY26 result, therefore, reflects a more normalized comparison when excluding such discontinued-operations effects.

Sequential trend: profit fell from the previous quarter

Despite the year-on-year increase, Strides’ Q4FY26 profit declined sequentially. The provided content said reported PAT fell 37.9% quarter-on-quarter from ₹208 crore. This indicates that the Q4 result, while stronger than last year, came off a higher base in the immediately preceding quarter. The company’s quarterly context suggests that geography mix and end-market demand conditions continue to influence near-term volatility.

Dividend recommendation for FY26

Alongside the results, Strides recommended a final dividend of ₹5 per share for the fiscal year. Dividend recommendations are closely watched because they reflect both cash-flow confidence and board-level capital allocation preferences. The announcement also adds a concrete shareholder-return datapoint to the FY26 outcome, which otherwise features large year-on-year profit swings driven by discontinued operations in FY25.

Snapshot of key numbers

The following table summarises the headline metrics explicitly stated in the provided material.

Full-year context in numbers

FY26 comparisons are best read with the discontinued-operations impact in mind.

Why the result matters for investors tracking Strides

The Q4FY26 update shows a clear split between market performance: stronger growth outside the US, and subdued conditions in the US business linked to a weak flu season. The year-on-year profit surge in Q4 looks meaningful, but it also sits alongside a sequential PAT decline from the prior quarter. At the full-year level, the large drop versus FY25 is primarily explained in the provided material by the discontinued-operations profit booked in FY25. For market participants, this combination of quarterly momentum outside the US and an uneven US backdrop remains central to how Strides’ earnings profile is read.

What to watch next

With a ₹5 per share final dividend recommended and management reiterating a focus on profitability amid global challenges, the next key datapoints will be whether the US segment sees a demand recovery and how ex-US growth sustains after a strong FY26 showing. Investors will also track how consistently the company converts operating performance into net profit, especially in quarters where exceptional items impact reported numbers.